Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06163131
Other study ID # KH02
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date November 27, 2023
Est. completion date April 1, 2027

Study information

Verified date November 2023
Source Aarhus University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

In some patients with chronic obstructive pulmonary disease (COPD) the breathlessness is caused by hyperinflation of the lungs. This causes difficulty breathing air out and makes it harder to breath in new air and limits the movement of the diaphram. The diaphragm is the muscle used for breathing between the chest and the stomach. Some of these patients can receive treatment with endobronchial valves, where one-ways are inserted into the bronchial system the let out some of the excess air, and thereby relieve breathlessness. The goal of this observational study is to investigate the effect of endobronchial valves on the mobility of the diaphragm in patients with chronic obstructive pulmonary disease. The main questions it aims to answer are: - If the movement of the diaphragm improves after treatment with endobronchial valves. - If there is a link between improvement of diaphragm function and improvement of symptoms, lung function and physical ability. - If ultrasound scan immediately after the treatment will predict which patients will benefit from the treatment. Participants will undergo ultrasound before, 1 day after and 90 days after the procedure, and lung function examinations from their already planned control visits will be collected.


Description:

When emphysema is present in COPD-patients, the impaired expiratory ventilation causes lung hyperinflation. This results in a change in the respiratory mechanisms of the thorax and thereby impairment of the movement capacity of the muscles. The most important respiratory muscle, the diaphragm, is caudally displaced and flattened, hence, the capacity and mobility of the muscle decreases. Some patients with COPD fulfill the criteria for treatment with endobronchial valves (EBV) where one-way valves can be inserted in the bronchial system. The mechanism behind the effect of EBV is believed to be formation of an atelectasis of the designated lobe and thereby reduction of hyperinflation and hence reduction of symptoms and increase in pulmonary function In this study the aim is to assess: 1. If the movement of the diaphragm improves after insertion of endobronchial valves in patients with severe emphysema. 2. If there is a correlation between improvement of diaphragm function and improvement of symptoms, lung function examinations and physical ability after insertion of endobronchial valves. 3. If immediate post-procedural ultrasound evaluation of diaphragm function predicts the development of atelectasis and hence clinical outcome


Recruitment information / eligibility

Status Recruiting
Enrollment 35
Est. completion date April 1, 2027
Est. primary completion date November 27, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients selected to receive treatment with endobronchial valves 2. Signed informed consent Exclusion Criteria: 1. Neuromuscular disease interfering with diaphragm function 2. Pleural effusion at time of preoperative or 90-days postoperative ultrasound

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Denmark Aarhus University Hospital Aarhus

Sponsors (1)

Lead Sponsor Collaborator
Aarhus University Hospital

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Diaphragm mobility The area method[13] will be used for assessment of diaphragm movement, using a curvilinear probe (2-6 MHz). Measurements will be performed during tidal respiration, deep respiration, sniff excursion and constant flow with constant volume, using test flute with bag of air attached. Before the procedure, 1 day after the procedure and 90 days after the procedure
Primary Diaphragm mobility M-mode: Diaphragm excursion in tidal, deep and sniff inspiration will be evaluated in the right side using M-mode through anterior subcostal midclavicular view. Contraction and relaxation velocity will be measured. Before the procedure, 1 day after the procedure and 90 days after the procedure
Primary Diaphragm Thickening Thickness and thickening ratio: The thickness and thickening ratio will be evaluated in B-mode using the linear probe, though lateral intercostal view during tidal respiration. Before the procedure, 1 day after the procedure and 90 days after the procedure
Secondary Forced expiratory volume in 1 second in litres Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Forced expiratory volume in 1 second % of expected Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Forced vital capacity in litres Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Forced vital capacity in % of expected Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Total lung volume in % of expected Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Residual volume in % of expected Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary diffusion capacity in % of expected Patients will undergo lung function examinations as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary 6 Minute walking test Patients will undergo 6 minutes walking test as a part of the independent preoperative and postoperative assessments Before and 90 days after the procedure
Secondary Rate of atelectasis on Lung X-ray Patients will receive x ray of the lungs as a part of the independent preoperative and postoperative assessments Before, one day and 90 days after the procedure
Secondary Medical Research Council (MRC) Dyspnoea Scale Medical Research Council (MRC) score will be used for symptom burden assessment Before, one day and 90 days after the procedure
Secondary COPD Assessment Test (CAT) Score CAT score will be used for symptom burden assessment Before, one day and 90 days after the procedure
See also
  Status Clinical Trial Phase
Completed NCT05102305 - A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
Completed NCT01867762 - An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease Phase 2
Recruiting NCT05562037 - Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA N/A
Terminated NCT04921332 - Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD N/A
Completed NCT03089515 - Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust N/A
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT05552833 - Pulmonary Adaptive Responses to HIIT in COPD N/A
Recruiting NCT05835492 - A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
Recruiting NCT05631132 - May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases? N/A
Completed NCT03244137 - Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
Not yet recruiting NCT03282526 - Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease N/A
Completed NCT02546700 - A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 2
Withdrawn NCT04446637 - Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD Phase 3
Completed NCT04535986 - A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD Phase 3
Recruiting NCT05865184 - Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
Completed NCT03256695 - Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD) Phase 3
Completed NCT03295474 - Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
Withdrawn NCT04042168 - Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD) Phase 4
Completed NCT03414541 - Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease Phase 2
Completed NCT02552160 - DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy